On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

The ACIP has voted to recommend the use of respiratory syncytial virus (RSV) vaccines for adults aged 50 to 59.

A federal panel of medical experts on Wednesday recommended an expansion of respiratory syncytial virus (RSV) vaccinations ...

US Advisory Committee on Immunization Practices recommends approval of GSK’s RSV vaccines, Arexvy for adults aged 50-59: London, UK Saturday, April 19, 2025, 09:00 Hrs [IST] GSK ...

More information: Michael G Ison et al, Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...